Skip to main content

Showing 9 matches for the following: Inventor: "McDonnell, Donald" ×

Melanoma treatment method using estrogen modulating small molecules

Melanoma treatment method using estrogen modulating small molecules

Unmet Need Metastatic melanoma, skin cancer that has spread, is an incredibly deadly cancer, with a median survivorship of 6-9 months. For patients with melanoma, a frequently used therapy is immune checkpoint blockade (ICB). These…

Read More

CaMKK2 as a target for cancer immunotherapy

CaMKK2 as a target for cancer immunotherapy

Tumor cells have the remarkable ability to block the immune system, and in such a way escape the immune response. This is a major problem that causes cancer development and metastasis. The ability of tumor…

Read More

Novel therapeutic targets in the androgen receptor signaling pathway for prostate cancer

Novel therapeutic targets in the androgen receptor signaling pathway for prostate cancer

Unmet Need Prostate cancer is the most common malignancy in men. The most recent CDC data demonstrates that prostate cancer makes up 12.2% all new cancer cases in the U.S. at 207,430. Prostate cancers express…

Read More

Estrogen Receptor Action Indicator (ERIN) Mouse

Estrogen Receptor Action Indicator (ERIN) Mouse

To address globally the issue of tissue specificity of ER ligands, Duke scientists have developed a transgenic mouse that functions as a reporter of ER activity, termed ERIN (estrogen receptor action indicator). ERIN provides a…

Read More

Long term estrogen deprived tumor models 71, 73 and 75

Long term estrogen deprived tumor models 71, 73 and 75

Long term estrogen deprived tumor models 71, 73, and 75 are estrogen receptor positive xenograft tumor models that grow independent of estrogen exposure, thereby providing an in vivo tumor model of aromatase resistance in the…

Read More

A reporter gene C3-T1ba

A reporter gene C3-T1ba

Reporter Gene used to measure both estrogen and tamoxifen activated estrogen receptor transcriptional activity reconstituted in mammalian cells. Derived from the complement 3 (C3) promotor.

Read More

Cell line model of enzalutamide resistant prostate cancer

Cell line model of enzalutamide resistant prostate cancer

Traditionally, AR drug discovery has used both ligand and AR structure-based design, seeking antagonists by classical ligand binding assays or cellular reporter assays that assess functional antagonism of androgen-dependent transcriptional activation. While these largely empirical…

Read More

Cell line model of castration resistant prostate cancer

Cell line model of castration resistant prostate cancer

Traditionally, AR drug discovery has used both ligand and AR structure-based design, seeking antagonists by classical ligand binding assays or cellular reporter assays that assess functional antagonism of androgen-dependent transcriptional activation. While these largely empirical…

Read More

HeLaDuke

HeLaDuke

Cell lines with enhanced sensitivity to estrogens and antiestrogens

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us